Substance / Medication

Amifampridine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Treatment for Lambert-Eaton myasthenic syndrome.
Keogh Michael, Sedehizadeh Saam, Maddison Paul · Cochrane Database Syst Rev · 2011
PMID: 21328260Meta-AnalysisFull text (PMC)
Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P, Newsom-Davis J · Cochrane Database Syst Rev · 2005
PMID: 15846654Meta-Analysis
Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P, Newsom-Davis J · Cochrane Database Syst Rev · 2003
PMID: 12804456Meta-Analysis
Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen Peter E, Musson Donald G, Hanson Boyd et al. · Clin Ther · 2015
PMID: 26101174RCT
Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).
Hatanaka Yuki, Mori-Yoshimura Madoka, Utsugisawa Kimiaki et al. · Intern Med · 2025
PMID: 40533232ObservationalFull text (PMC)
Amifampridine phosphate in congenital myasthenic syndrome.
Verma Sumit, Mazell Shawnay N, Shah Durga A · Muscle Nerve · 2016
PMID: 27348204Case Report
Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
Shieh Perry, Sharma Khema, Kohrman Bruce et al. · J Clin Neuromuscul Dis · 2019
PMID: 30801481TrialFull text (PMC)
Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh Shin J, Shcherbakova Natalya, Kostera-Pruszczyk Anna et al. · Muscle Nerve · 2016
PMID: 26852139Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amifampridine phosphate (substance)
SNOMED CT
18038211000001106
UMLS CUI
C2917064

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.